Nemaura Medical (NMRD) Stock Price
Nemaura Medical Price
Nemaura Medical's net margin stands at -18,358.0%, down from -2,755.8% several years earlier.
Nemaura Medical stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Nemaura Medical business model & stock analysis
Frequently asked questions about Nemaura Medical
The business model of Nemaura Medical Inc. revolves around developing and commercializing innovative medical devices and digital healthcare solutions. Nemaura Medical specializes in creating non-invasive, continuous glucose monitoring (CGM) systems for diabetes management. Their flagship product, SugarBEAT®, offers a needle-free patch that measures glucose levels through the skin, providing real-time data to users. By combining cutting-edge technology with user-friendly design, Nemaura Medical aims to empower individuals with diabetes to manage their condition effectively and improve overall quality of life.
Nemaura Medical Inc primarily operates in the healthcare and pharmaceutical industries.
The main competitors of Nemaura Medical Inc in the market include DexCom Inc, Abbott Laboratories, Medtronic plc, and Senseonics Holdings Inc.
Nemaura Medical Inc is a renowned healthcare company founded in 2011. Headquartered in Loughborough, United Kingdom, the company specializes in developing innovative medical technology solutions. Nemaura Medical Inc focuses on creating non-invasive medical devices for continuous glucose monitoring and other wearable technologies. With a strong commitment to improving patient outcomes and quality of life, the company's cutting-edge products have gained recognition worldwide. Nemaura Medical Inc has consistently demonstrated its dedication to researching, developing, and commercializing advanced healthcare solutions, making it a leading player in the industry.
Nemaura Medical Inc has achieved significant milestones in its journey. The company successfully developed and launched the sugarBEAT, a non-invasive continuous glucose monitoring device that helps individuals manage their diabetes effectively. In addition, Nemaura Medical Inc received the CE mark approval for sugarBEAT, enabling European market access. The company also obtained FDA clearance for its sugarBEAT system, allowing it to enter the lucrative U.S. market. Nemaura Medical Inc has made remarkable strides in product innovation, regulatory approvals, and market expansion, solidifying its position as a prominent player in the healthcare technology sector.
Nemaura Medical Inc is primarily present in the United States, United Kingdom, Europe, and parts of Asia.
Nemaura Medical Inc represents values of innovation, quality, and social responsibility in the healthcare industry. With a strong corporate philosophy focused on improving patient outcomes, Nemaura Medical Inc is committed to developing innovative medical devices and solutions. The company strives to provide cutting-edge technologies and deliver superior healthcare products that meet the needs of patients and healthcare providers. By prioritizing research and development, Nemaura Medical Inc aims to revolutionize the way medical conditions are diagnosed, monitored, and managed. With a customer-centric approach, the company's products are designed to enhance quality of life and improve overall healthcare experiences for individuals around the world.
7 analysts currently rate the Nemaura Medical stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Nemaura Medical to generate revenue of 3.40 M USD and earnings per share of -0.30 USD.
Converted at the current exchange rate, the Nemaura Medical share trades at 0.00 EUR (0.00 USD).
The Nemaura Medical share (NMRD) is listed on 2 stock exchanges, including: NASDAQ (NMRD), Frankfurt (N18A.F).
Nemaura Medical Inc is a medical technology company headquartered in the United Kingdom. It was founded in 2011 by Dr. Faz Chowdhury and aims to develop innovative health solutions that improve people's lives. The company specializes in the development of products in the areas of drug delivery, continuous glucose monitoring, and vital signs monitoring. Nemaura Medical focuses on developing wearable technology solutions capable of storing and analyzing medical measurements. The company offers a wide range of products and services tailored to the needs of doctors, hospitals, and patients. A key area of business for Nemaura Medical is continuous glucose monitoring. The company has developed the groundbreaking SugarBEAT system, which allows for continuous monitoring of blood sugar levels without the patient needing to wear a sensory patch on their skin. The SugarBEAT system is expected to be introduced in various markets worldwide. Another important area of business for Nemaura Medical is smartpatch delivery. The company is developing a product that uses a patch inserted into the skin with a needle or ultrasound device to administer medication. The patch can remain on the skin, and the medication is continuously or intermittently delivered. Nemaura Medical also has a portfolio of electronic vital signs. The company is developing a product that enables non-invasive monitoring of smartwatch-based vital signs such as pulse rate, respiratory rate, and oxygen saturation. Nemaura Medical's business model is focused on providing innovative health solutions that improve people's quality of life. The company generates revenue from the sale of its products and services, as well as from licensing fees and partnerships. Nemaura Medical has formed partnerships with various companies to introduce its technology into various areas of medicine. This includes collaborations with companies in the field of diabetology and the medical technology industry. Overall, Nemaura Medical is a leading provider of wearable technology solutions in the field of continuous monitoring and drug delivery. The company has developed an innovative portfolio of products aimed at improving patients' quality of life.
The expected revenue of Nemaura Medical is 3.40 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Nemaura Medical is -8.58 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Nemaura Medical is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Nemaura Medical stock.
The price-to-sales ratio (P/S) of Nemaura Medical is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Nemaura Medical stock.
The Eulerpool Quality Score for Nemaura Medical is 4/10.
The ISIN of Nemaura Medical is US6404422080. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Nemaura Medical is A2PWNG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Nemaura Medical is NMRD. The ticker symbol is used to trade Nemaura Medical shares on the stock exchange.
Nemaura Medical stock
Nemaura Medical Peer Group
Nemaura Medical Ticker
Nemaura Medical FIGI
All fundamentals and in-depth analysis of Nemaura Medical
Our stock analysis for Nemaura Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nemaura Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.